QIA.DE Qiagen N.V. (XETRA) pre-market 30 Jan 2026: Earnings Feb 4 may reprice shares
Qiagen N.V. (QIA.DE) trades at €44.72 in pre-market XETRA trading as investors focus on the upcoming earnings release on 2026-02-04. QIA.DE stock faces a test on revenue mix and margins after recent guidance swings and board changes. We outline the numbers investors will watch, the valuation context, and short-term catalysts that could move the stock.
Earnings snapshot and calendar for QIA.DE stock
Qiagen reports earnings on 2026-02-04 at 16:30 UTC; that date is the primary near-term catalyst for QIA.DE stock. Analysts will watch reported EPS, organic revenue growth, and margins versus consensus given FY2024 weakness in net income and EPS. Management commentary on product mix, specifically consumables like QuantiFERON and QIAcuity demand, will drive the reaction.
Price, volume and technicals for QIA.DE stock
Pre-market price is €44.72, day low €44.45, day high €45.35, and volume 504,376 versus average 586,255. Momentum indicators show RSI 65.64 and MACD histogram 0.29, signalling near-term strength but limited trend conviction. Short-term traders should note the 50-day average €42.05 and 200-day average €42.17, which remain below the current price.
Valuation and fundamentals: how QIA.DE stock stacks up
Qiagen reports EPS €1.64 and a trailing PE of 27.03, with market cap around €9,178,201,508.00. Key ratios include price-to-sales 5.30, price-to-book 3.15, and dividend per share €2.73 (yield ~5.14%). Compared with Healthcare peers (average PE ~33.27), QIA.DE stock trades at a modest PE discount while offering higher dividend yield, signalling income-oriented value for some investors.
Meyka AI grade, forecasts and price targets for QIA.DE stock
Meyka AI rates QIA.DE with a score of 71.31 out of 100 — Grade B+, Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of €40.22, implying -9.98% versus the current €44.72; monthly and quarterly projections are €38.68 and €35.18 respectively. Forecasts are model-based projections and not guarantees. Practical price targets: conservative €35.00, base €44.00, bull €50.00, reflecting range-bound risks into earnings.
Catalysts, takeover optionality and corporate moves affecting QIA.DE stock
Recent industry commentary highlights takeover optionality given Qiagen’s attractive consumables franchise and stable cash flows; see a detailed note on strategy and optionality source. Qiagen also appointed Mark Stevenson to the supervisory board, a governance update investors view as positive for strategic oversight source. These items are potential upside catalysts if earnings show margin recovery or stronger consumables growth.
Risks, sector context and trading considerations for QIA.DE stock
Key risks include slower PCR and NGS consumable demand, margin pressure from pricing, and FX headwinds. Debt metrics are moderate: net-debt-to-EBITDA ~0.94 and debt-to-equity 0.58, while current ratio 2.60 supports liquidity. Healthcare sector performance is muted YTD; sector average returns and valuations mean QIA.DE stock can lag if diagnostics demand softens.
Final Thoughts
Key takeaways: QIA.DE stock trades at €44.72 ahead of earnings on 2026-02-04, with market attention on EPS €1.64, trailing PE 27.03, and margin commentary. Meyka AI rates QIA.DE 71.31/100 (B+, BUY) and models a yearly price of €40.22, implying -9.98% from today’s price; this highlights downside risk if results disappoint. However, a strong consumables print, better-than-expected margins, or concrete strategic moves could push valuation toward our base €44.00 or bull €50.00 target. Use cautious position sizing into the print and monitor volume and guidance closely. For a quick drill-down of live metrics, see the Meyka stock page for QIA.DE at Meyka stock page. Meyka AI-powered market analysis provides model-based forecasts and grades, not investment advice; always validate with your own research.
FAQs
When does Qiagen report earnings and what matters most?
Qiagen reports on 2026-02-04; investors will focus on EPS, organic revenue, gross margins, and guidance. QIA.DE stock reaction will hinge on consumables demand and margin drivers, plus any updates on M&A optionality or restructuring.
What valuation metrics should I watch for QIA.DE stock?
Key metrics are trailing PE 27.03, EPS €1.64, price-to-sales 5.30, price-to-book 3.15, and dividend yield ~5.14%. Compare these to Healthcare peers to assess relative value and income trade-offs.
What does Meyka AI forecast for QIA.DE stock after earnings?
Meyka AI’s forecast model projects a yearly price of €40.22, implying -9.98% from the current €44.72. Forecasts are model-based projections and not guarantees; results and guidance can change the outlook.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
